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OBJECTIVES We examined whether patients with ischemic heart disease (IHD) should be treated with
nicorandil, an adenosine triphosphate-sensitive potassium channel opener, in addition to the
regular use of nitrates.
BACKGROUND It has been reported that nicorandil possibly has additive effects on nitroglycerin (NTG)
treatment for angina, but the mechanism is not clear.
METHODS We directly measured anterograde coronary blood flow (CBF) with a Doppler guide wire to
examine the effects of intravenous administration of NTG (0.3 mg) and nicorandil (6 mg)
during continuous administration of NTG at a sufficient dose (25 mg/min) in subjects with
normal and stenotic coronary arteries.
RESULTS Additional systemic administration of NTG decreased anterograde CBF (normal 219.7%;
stenotic 221.2%). In contrast, nicorandil increased anterograde CBF in both normal (54.6%)
and stenotic (89.6%) coronary arteries, without the coronary steal phenomenon. There was a
tendency toward nicorandil-dilated diameters in the patients with stenotic arteries (p 5 0.06).
There were no effects of additional administration on pulmonary artery wedge pressure. There
was no difference in changes in heart rate and mean aortic blood pressure between NTG and
nicorandil therapy.
CONCLUSIONS These results suggest that in patients treated with nitrates, additional administration of
nicorandil is more useful, in terms of increasing CBF, than additional administration of
nitrates. Adjunctive use of nicorandil with nitrates may provide the further benefit of
myocardial protection and may improve the prognosis of patients with IHD. (J Am Coll
Cardiol 2001;37:719–25) © 2001 by the American College of Cardiology
Nitrates are frequently administered to patients with isch-
emic heart disease (IHD). It is proposed that nitrates exert
their benefits by decreasing myocardial oxygen consumption
with cardiac unloading and by increasing regional myocar-
dial blood flow. Regional myocardial blood flow is regulated
by anterograde flow through the coronary arteries, including
stenotic lesions, and by retrograde flow through collateral
arteries. Anterograde coronary blood flow (CBF) is deter-
mined mainly by diastolic blood pressure, coronary stenosis
severity and microvascular resistance, which is important for
oxygen supply to the myocardium. However, the effects of
nitrates on anterograde CBF are still controversial.
Fallen et al. (1) showed, by using scintigraphy, that
topical nitroglycerin (NTG) in a skin patch increased
regional blood flow in patients with IHD, without a
reduction in blood pressure. However, 7 of 10 patients in
this study had collateral arteries. Therefore, the result of
Fallen’s study may only mean that retrograde blood flow
through the collateral arteries increased. Other studies
measuring great vein blood flow showed that intravenous or
sublingual administration of NTG decreased regional blood
flow, with a reduction in blood pressure (2,3). There is no
study of direct measurement of anterograde CBF to evaluate
the effects of NTG. The limitation of nitrates in improving
the prognosis of patients with IHD, as shown in the
Nifedipine Angina Myocardial Infarction Study (NAMIS)
(4) and the fourth International Study of Infarct Survival
(ISIS-4) (5), may be partly due to a failure to improve CBF.
Nicorandil, N-(2-hydroxyethyl)-nicotinamide (a nitrate),
is an antianginal drug that causes coronary vasodilation of
both epicardial and resistance vessels, with little reduction in
blood pressure (6–8). These effects are correlated with
activation of the adenosine triphosphate (ATP)-sensitive
potassium channel and increased production of cyclic guan-
ylate monophosphate (9,10). There are several reports
comparing the effects of nicorandil and NTG on hemody-
namic variables, including CBF and the microvascular
response (11–13). It has also been reported that nicorandil
is more effective in relieving ischemia in patients with
unstable angina, as compared with NTG (14), and nicoran-
dil reduced the number of unstable angina attacks unre-
sponsive to nitrates (15). Suryapranata et al. (16) reported
that intracoronary injection of nicorandil after isosorbide
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dinitrate also dilated stenotic diameters. However, intra-
coronary injection is quite different from oral or intravenous
administration, which is the normal use of nicorandil.
Systemic administration might cause coronary steal and a
reduction in preload, which will affect CBF. Therefore, we
hypothesized that systemic administration of nicorandil in
addition to NTG would be more effective in increasing
anterograde CBF, as compared with NTG alone, without
causing the coronary steal phenomenon in patients with
IHD (17).
In the present study, we used a Doppler guide wire to
directly measure anterograde CBF. We determined the dose
response of CBF to systemic administration of NTG and
examined the effects of systemic administration of NTG
and nicorandil during continuous administration of a suffi-
cient dose of NTG in subjects with normal coronary
arteries. Furthermore, we examined these effects in patients
with stenotic coronary arteries to clarify whether additional
administration of nicorandil to NTG has a beneficial effect
on CBF, or a detrimental effect on CBF, due to the
coronary steal phenomenon in at-risk areas. We believe that
the present study provides useful information on whether
patients with IHD should be treated with nicorandil in
addition to the regular use of nitrates.
METHODS
Study group. Table 1 shows the clinical characteristics of
each subject. First, by using the Doppler guide wire, we
studied the dose-response effects of NTG to investigate the
direct effect of NTG on CBF. The study group consisted of
four patients who were being evaluated for atypical chest
pain or who were undergoing follow-up percutaneous trans-
luminal coronary angioplasty (PTCA). In the cases of
follow-up PTCA, untargeted vessels were studied. All
subjects had normal coronary arteries on angiography.
In the study of the effects of NTG and nicorandil during
continuous administration of NTG, the group with normal
coronary arteries consisted of six patients who were also
being evaluated for atypical chest pain or who were under-
going follow-up PTCA. In the cases of follow-up PTCA,
untargeted vessels were studied. All subjects had normal
coronary arteries on angiography or lesions with ,25%
lumen narrowing and normal left ventricular function. The
group with stenotic coronary arteries consisted of six pa-
tients with angiographic evidence of coronary atherosclero-
sis. All patients had at least one lesion with .50% lumen
narrowing of a major coronary artery branch. Patients with
acute myocardial infarction, congestive heart failure, total
occlusion of a target vessel or angiographically visible
collateral vessels were excluded. The Committee for the
Protection of Human Subjects in Research at our institute
Abbreviations and Acronyms
APV 5 averaged peak (blood) velocity
ATP 5 adenosine triphosphate
CBF 5 coronary blood flow
CSA 5 cross-sectional area
IHD 5 ischemic heart disease
LAD 5 left anterior descending coronary artery
LCA 5 left coronary artery
LCx 5 left circumflex coronary artery
NTG 5 nitroglycerin
PTCA 5 percutaneous transluminal coronary angioplasty
Table 1. Baseline Characteristics
Patient No.
Coronary
Artery
Diameter
Stenosis Diagnosis
Age (yrs)/
Gender HT DM HL Smoking Drugs
Dose-response effects of NTG
1 LAD , 10% Follow-up PTCA 63/M 1 2 2 1 N
2 LAD , 10% Follow-up PTCA 77/M 2 2 2 2 N
3 LAD , 10% NCA 61/M 1 2 2 1 A, C, N
4 LAD , 10% Arrhythmia 53/M 2 2 1 2 N
Effects of NTG and nicorandil during continuous administration of NTG
Patients with normal coronary arteries
1 LAD , 10% NCA 52/F 1 2 1 2 A, B, C
2 LAD , 10% Follow-up PTCA 54/F 1 2 2 2 A, B, C
3 LAD , 10% NCA 62/M 1 2 2 2 C, N
4 LCx , 10% Arrhythmia 56/M 1 1 2 1 A, B, C
5 LAD , 10% NCA 54/M 1 2 1 2 A
6 LCx , 10% Follow-up PTCA 54/M 1 2 1 2 A, C
Patients with stenotic coronary arteries
1 RCA 55% EA 59/M 1 1 2 1 N, A
2 LAD 65% EA 67/M 1 2 2 1 A, N
3 LAD 62% EA 57/M 1 1 2 1 A, B, C
4 LCx 53% EA 59/M 1 2 1 2 N
5 LAD 97% with delay EA 59/M 1 1 2 1 N, A
6 LAD 78% EA 64/M 2 2 2 2 N
A 5 angiotensin-converting enzyme inhibitor; B 5 beta-blocker; C 5 calcium channel blocker; DM 5 diabetes mellitus; EA 5 effort angina; F 5 female; HL 5 hyperlipidemia;
HT 5 (arterial) hypertension; LAD 5 left anterior descending coronary artery; LCx 5 left circumflex artery; M 5 male; N 5 nitrate; NCA 5 neurocirculatory asthenia; NTG 5
nitroglycerin; PTCA 5 percutaneous transluminal coronary angioplasty; RCA 5 right coronary artery.
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approved the study protocol, and written, informed consent
was obtained from each patient.
Study protocol. The protocol design is presented in Figure
1. All antihypertensive agents and medications that affect
cardiac function were withheld for .24 h before cardiac
catheterization.
In the study of the dose-response effects of systemic
administration of NTG, 20 min after diagnostic coronary
angiography, heart rate, aortic blood pressure, CBF velocity
and coronary angiography were recorded throughout the
study. Bolus doses of 0.01, 0.05, 0.1, 0.3, 0.5 and 0.8 mg of
NTG were injected intravenously over a 20-s period at
5-min intervals.
In the study of the effects of NTG and nicorandil during
continuous administration of NTG, continuous intravenous
infusion of NTG (25 mg/min) was begun 2 h before
catheterization to achieve maximal vasodilation of the epi-
cardial coronary arteries. Twenty minutes after diagnostic
coronary angiography, heart rate, aortic blood pressure,
pulmonary artery wedge pressure and CBF velocity were
also recorded throughout the procedure. A bolus dose of
NTG (0.3 mg) was injected intravenously over a 20-s
period, and hemodynamic changes, CBF velocity and cor-
onary angiographic measurements were recorded for 5 min.
After a further 15-min interval, during which CBF velocity
returned completely to the rest level, a bolus dose of
nicorandil (6 mg) (Chugai Pharmaceutical Co., Tokyo,
Japan) was injected intravenously over a 20-s period. He-
modynamic changes, CBF velocity and coronary angio-
graphic measurements were also recorded for 5 min. Then,
PTCA was performed in the group with stenotic coronary
arteries.
Measurement of CBF velocity and CBF. In patients with
normal coronary arteries, the 0.014-in. (0.035-cm) Doppler
guide wire (Flowire, Cardiometrics, Inc., Mountain View,
California) was placed in the mid portion of the left anterior
descending coronary artery (LAD). In patients with coro-
nary artery stenosis, the Doppler guide wire was inserted
distal to the stenotic lesion. The tip of the Doppler guide
wire was positioned distal to the second diagonal branch of
the LAD, distal to the obtuse marginal branch of the left
circumflex artery (LCx) or distal to the atrioventricular
branch of the right coronary artery. Furthermore, when the
stenotic lesion was in the left coronary artery (LCA), we
inserted another Doppler catheter into the nonstenotic
coronary artery of the LCA to examine the coronary steal
phenomenon.
Peak CBF velocity was continuously monitored using a
fast Fourier transform–based spectral analyzer (FlowMap,
Cardiometrics Inc.). Averaged peak (blood) velocity (APV)
signals were obtained, and mean CBF was calculated as
follows: CBF (ml/min) 5 0.5 3 averaged peak CBF
velocity (cm/min) 3 coronary cross-sectional area (CSA)
(cm2).
Quantitative coronary angiography. Coronary cineangio-
grams were recorded with a cineangiographic system (Sie-
mens Inc., Tokyo, Japan). We determined changes in the
lumen diameter of the target coronary artery, a segment 2 to
3 mm distal to the tip of the Doppler guide wire. Measure-
ments were performed on end-diastolic frames with a
Cardiac Analyzer for Macintosh (CAM-1000, Nishimoto
Co., Osaka, Japan), which allowed automatic edge detec-
tion. The diameter of the coronary catheter served as the
angiographic reference. Measurements of diameter were
performed three times in a blinded manner, without knowl-
edge of the clinical characteristics of the patients.
Statistics. All data are given as the mean value 6 SEM.
For all statistical analyses, we used the StatView computer
software application (SAS Institute, Cary, North Carolina).
Differences in hemodynamic variables, coronary diameter,
CSA, APV and CBF between NTG and nicorandil admin-
istration and between the normal and stenotic coronary
artery groups were analyzed by two-way repeated measures
analysis of variance, with appropriate interactions, followed
by the Scheffe´ multiple comparisons procedure. The paired
Student t test was used to analyze the dose-response effects
of NTG on CBF and the effects of NTG or nicorandil on
epicardial coronary artery diameter during continuous ad-
ministration of NTG. Clinical characteristics, such as age
and body mass index, were compared by unpaired the
Student t test.
RESULTS
Dose-response effects of NTG on CBF. We measured
heart rate, blood pressure, CSA, APV and CBF at 1 min
after NTG administration. Nitroglycerin gradually in-
creased heart rate and decreased mean blood pressure in a
dose-dependent manner (date not shown). Nitroglycerin
also gradually increased CSA, but decreased APV. Conse-
quently, CBF was not changed at doses of 0.01 and 0.05 mg
of NTG, but was significantly decreased at doses of 0.1, 0.3,
0.5 and 0.8 mg of NTG (Table 2).
Effects of NTG and nicorandil on epicardial coronary
artery diameter. Table 3 shows the effects of NTG and
nicorandil on epicardial coronary artery diameter. Coronary
diameter after NTG or nicorandil was individually mea-
Figure 1. Protocol design. i.v. 5 intravenous; NTG 5 nitroglycerin.
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sured as the maximal dilation in the period of 5 min after
drug administration. During continuous systemic adminis-
tration of NTG (25 mg/min), there was a tendency (p 5
0.06) toward nicorandil-dilated obstructive diameters and
post-stenotic diameters, where the tip of the Doppler guide
wire was positioned, in the group with stenotic coronary
arteries.
Effects of NTG and nicorandil on hemodynamic vari-
ables in the normal coronary artery group (Fig. 2). Heart
rate was significantly increased 30 s after administration of
NTG (from 66 6 3 to 77 6 5 beats/min, p , 0.01) and
nicorandil (from 69 6 5 to 75 6 5 beats/min, p , 0.05).
These increases were sustained for 1 min after both NTG
and nicorandil administration.
Mean blood pressure was significantly decreased 30 s after
administration of NTG (from 102 6 3 to 89 6 4 mm Hg,
p , 0.01) and nicorandil (from 97 6 4 to 89 6 5 mm Hg,
p , 0.05).
After continuous intravenous infusion of NTG, no sig-
nificant change in CSA occurred (data not shown). Nitro-
glycerin significantly decreased APV and CBF, which were
lowest 2 min after injection of NTG (APV 220.0 6 5.6%;
CBF 219.7 6 5.4%, p , 0.01). This decrease was sustained
for 4 min. However, nicorandil increased APV and CBF,
which were highest 30 s after injection of nicorandil (APV
53.5 6 20.4%; CBF 54.6 6 21.8%; p , 0.01). These
increases were sustained for 2 min (Fig. 2). It is noteworthy
that the time course of changes in APV and CBF was
markedly different between NTG and nicorandil.
Effects of NTG and nicorandil on hemodynamic vari-
ables in the stenotic coronary artery group (Fig. 3). Heart
rate was significantly increased 30 s after administration of
NTG (from 64 6 4 to 74 6 6 beats/min, p , 0.05) and
nicorandil (from 64 6 4 to 71 6 3 beats/min, p , 0.01).
These increases were sustained for 3 min after administra-
tion of both NTG and nicorandil.
Mean aortic blood pressure was significantly decreased
30 s after the administration of NTG (from 105 6 7 to
98 6 6 mm Hg, p , 0.05) and nicorandil (from 101 6 6 to
85 6 5 mm Hg, p , 0.01). These decreases were sustained
for 4 and 3 min, respectively.
There were no changes in the time course of pulmonary
artery wedge pressure.
After continuous intravenous infusion of NTG, no sig-
nificant change in CSA occurred with an additional NTG
injection (data not shown). Nitroglycerin injection de-
creased APV and CBF. In contrast, nicorandil increased
APV and CBF, which were highest 30 s after the injection
of nicorandil (APV 89.2 6 41.1%; CBF 89.6 6 42.4%, p ,
0.05). These increases were sustained for 4 min.
Comparison of the effects of nicorandil on normal cor-
onary arteries and stenotic coronary arteries in the ste-
notic coronary artery group. The diversion of CBF in the
LAD and LCx, as measured with two Doppler guide wires
in the stenotic coronary artery group, showed that there was
no significant difference in the effect of nicorandil on the
percent change in anterograde CBF between the normal
side and the stenotic side of the LCA (1 min: 84.2 6 31.4%
vs. 83.4 6 21.0%; 2 min: 34.6 6 11.2% vs. 38.4 6 14.6%).
DISCUSSION
Additive effects of intravenous nicorandil. This study
demonstrated, for the first time, to our knowledge, that
during continuous administration of NTG at a sufficient
dose, additional intravenous administration of NTG de-
Table 2. Dose-Response Effects of Nitroglycerin on Cerebral Blood Flow
Variables
NTG (mg)
Control 0.01 0.05 0.1 0.3 0.5 0.8
CSA (mm2) 7.17 6 1.32 7.28 6 1.39 7.30 6 1.38 7.35 6 1.37* 7.67 6 1.59* 8.00 6 1.67* 8.22 6 1.64*
APV (cm/s) 28.0 6 4.0 26.8 6 4.1 25.3 6 3.8* 24.5 6 3.5* 23.5 6 3.6* 21.5 6 3.3* 20.6 6 3.2*
CBF (cm3/min) 54.3 6 4.2 53.6 6 4.2 50.9 6 4.2 49.9 6 4.4* 49.3 6 3.8* 46.8 6 2.9* 46.3 6 2.5*
*p , 0.05 vs. control. Data are presented as the mean value 6 SEM.
APV 5 averaged peak (blood) velocity; CBF 5 coronary blood flow; CSA 5 (coronary) cross-sectional area; NTG 5 nitroglycerin.
Table 3. Effects of Nitroglycerin or Nicorandil on Epicardial Coronary Artery Diameter During
Continuous Administration of Nitroglycerin
Coronary Diameter (mm)
NTG (0.3 mg) Nicorandil (6 mg)
Before After Before After
Normal coronary arteries (n 5 6)
Coronary artery diameter 2.71 6 0.26 2.72 6 0.26 2.71 6 0.26 2.72 6 0.27
Stenotic coronary arteries (n 5 6)
Reference diameter 3.27 6 0.34 3.29 6 0.34 3.27 6 0.35 3.27 6 0.35
Obstruction diameter 1.05 6 0.26 1.06 6 0.27 1.05 6 0.28 1.07 6 0.25
Coronary artery diameter (Doppler flow wire) 2.48 6 0.20 2.49 6 0.19 2.48 6 0.20 2.50 6 0.20
Data are expressed as the mean value 6 SEM.
NTG 5 nitroglycerin.
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creased anterograde CBF; however, nicorandil increased
anterograde CBF in both normal and stenotic coronary
arteries. We reconfirmed, using direct measurement, that
high dose NTG worsened anterograde CBF without pre-
treatment with NTG (2,3). This result is probably due to an
excess reduction of preload and afterload, and resultant
tachycardia.
Furthermore, we demonstrated that nicorandil did not
cause the coronary steal phenomenon in patients with IHD.
We inserted two Doppler guide wires into both the LAD
and LCx and demonstrated that nicorandil significantly
increased anterograde CBF beyond the stenotic lesions. Of
interest, nicorandil also increased rather than decreased
anterograde CBF by 14% in patient no. 5 (with 97%
stenosis) and by 64% in patient no. 6 (with 78% stenosis).
Possible mechanisms. This different reaction between
NTG and nicorandil could not be related to the effects on
heart rate and blood pressure, because there were no
significant differences in heart rate and blood pressure at the
same times after administration of NTG and nicorandil.
Nitrate tolerance might modify the effect of additional
NTG on anterograde CBF. However, a reduction of CBF
by NTG was also observed without continuous pretreat-
ment with NTG.
We think that there are two possible mechanisms by
which nicorandil is capable of further increasing post-
stenotic CBF. The first is that nicorandil might dilate the
stenotic segments. It has been reported that intracoronary
injection of nicorandil after isosorbide dinitrate also dilated
stenotic diameters (16). Therefore, it is reasonable that
systemic administration of nicorandil also dilated the epi-
cardial stenotic segments that were already dilated by
continuous administration of NTG. In this study, however,
we could only detect the tendency of the additive effects of
nicorandil on the stenotic lesions. Because the coronary
arteries were already dilated during continuous administra-
tion of NTG, the additive changes in diameter might be
small. The other possible mechanism is that nicorandil
might function chiefly in the ischemic area, where the
intracellular ATP level is reduced. It has been reported that
nicorandil could activate KATP channels in the ischemic area
at a lower dose (2 to 3 mmol/liter), which would not activate
KATP channels in the nonischemic area (18). Therefore, it is
possible that nicorandil might cause adequate distribution of
CBF in ischemic regions through the dilation of coronary
resistance vessels.
Study limitations. Nicorandil is usually administered
orally or intravenously to obtain an effect additional to that
of NTG in patients with IHD. These administration
methods are slightly different from the present method of
intravenous bolus administration. However, in the present
study, the duration of cardiac catheterization was limited for
Figure 2. Effects of nitroglycerin (NTG) (solid circles, n 5 6) and nicorandil (open circles, n56) on heart rate (HR), mean arterial pressure (MAP),
averaged peak (blood) velocity (APV) and coronary blood flow (CBF) in the group with normal coronary arteries. *p , 0.01 vs. NTG.
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clinical reasons, especially in patients with coronary artery
stenosis, who underwent PTCA after the study.
We have demonstrated an additive effect of nicorandil on
CBF during NTG treatment; however, additive anti-
ischemic effects of nicorandil in the ischemic patient should
be addressed in the future clinical studies.
Conclusions. These results demonstrated the safety of
nicorandil without the occurrence of the coronary steal
phenomenon, as well as the beneficial effect on anterograde
CBF of additional administration of nicorandil to NTG
over NTG alone. Ito et al. (19) also reported that intrave-
nous administration of nicorandil preserved myocardial
viability in patients with reperfused acute myocardial infarc-
tion. Of interest, in their study, as well as in our study, most
patients were concomitantly treated with nitrates. There-
fore, we speculate that the increased anterograde CBF by
additional administration of nicorandil can provide further
benefit of myocardial protection in patients with IHD
treated with NTG. A further clinical study is needed to
examine whether treatment with both NTG and nicorandil
can improve the long-term prognosis of patients with IHD.
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